Mandar Deepak Muzumdar, MD
Associate Professor of Genetics and of Internal Medicine (Medical Oncology).Cards
Appointments
Additional Titles
Member, Yale Cancer Biology Institute
Scientific Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center
Co-Director of Pancreas Program, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center
Associate Professor of Internal Medicine, Medical Oncology
Contact Info
Genetics
Department of Genetics, P.O. Box 208005
New Haven, CT 06520-8005
United States
Appointments
Additional Titles
Member, Yale Cancer Biology Institute
Scientific Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center
Co-Director of Pancreas Program, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center
Associate Professor of Internal Medicine, Medical Oncology
Contact Info
Genetics
Department of Genetics, P.O. Box 208005
New Haven, CT 06520-8005
United States
Appointments
Additional Titles
Member, Yale Cancer Biology Institute
Scientific Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center
Co-Director of Pancreas Program, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center
Associate Professor of Internal Medicine, Medical Oncology
Contact Info
Genetics
Department of Genetics, P.O. Box 208005
New Haven, CT 06520-8005
United States
About
Titles
Associate Professor of Genetics and of Internal Medicine (Medical Oncology).
Member, Yale Cancer Biology Institute; Scientific Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center; Co-Director of Pancreas Program, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center; Associate Professor of Internal Medicine, Medical Oncology
Biography
Dr. Muzumdar graduated from Harvard College and received his Doctorate of Medicine from the Stanford University School of Medicine. He completed his internship and residency in Internal Medicine at Brigham and Women's Hospital and a fellowship in Medical Oncology at the Dana-Farber Cancer Institute and Massachusetts General Hospital. He completed a postdoctoral research fellowship at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology before joining the Yale faculty.
Learn more about Dr. Muzumdar>>
His laboratory is interested in understanding the mechanisms by which genetic, environmental, and host factors contribute to cancer initiation, progression, and maintenance. Leveraging a combination of sophisticated genetically-engineered cell and animal models, the lab seeks to define the molecular basis for tumor cell and host adaptations that drive tumorigenesis. Furthermore, the lab uses genetic and pharmacologic approaches combined with novel nanoparticle-based delivery methods to augment or impede these adaptations and determine the consequences on cancer development in these models. The ultimate goal of this research is to identify novel approaches for cancer prevention and treatment.
Appointments
Genetics
Associate Professor on TermPrimaryMedical Oncology
Associate Professor on TermSecondary
Other Departments & Organizations
- Genetics
- Genomics, Genetics, and Epigenetics
- Hepatic Arterial Infusion (HAI) Program
- Hyperthermic intraperitoneal chemotherapy (HIPEC) Program
- Internal Medicine
- Medical Oncology
- Molecular Cell Biology, Genetics and Development
- Molecular Medicine, Pharmacology, and Physiology
- Muzumdar Lab
- Oligometastatic Cancer Program
- Yale Cancer Biology Institute
- Yale Cancer Center
- Yale Combined Program in the Biological and Biomedical Sciences (BBS)
- Yale Fibrosis Program
- Yale Medicine
Education & Training
- Postdoctoral Research Fellow
- Koch Institute at MIT (2017)
- Clinical Fellow
- Dana-Farber Cancer Institute and Massachusetts General Hospital (2014)
- Resident in Internal Medicine
- Brigham and Women's Hospital (2010)
- Intern in Internal Medicine
- Brigham and Women's Hospital (2009)
- MD
- Stanford University School of Medicine (2008)
- AB
- Harvard College, Biochemical Sciences (2003)
Research
Overview
Medical Subject Headings (MeSH)
ORCID
0000-0001-7424-7223- View Lab Website
Muzumdar Lab
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Kallol Gupta, PhD
Lauren Lawres, MSPH
Moitrayee Bhattacharyya, PhD
Daniel Zelterman, PhD
Jeremy B. Jacox, MD, PhD
Jeremy Kortmansky, MD
Carcinoma, Pancreatic Ductal
Cell Proliferation
Carcinogenesis
Diabetes Mellitus
Obesity
Genes, Tumor Suppressor
Publications
Featured Publications
Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma
Chung KM, Singh J, Lawres L, Dorans KJ, Garcia C, Burkhardt DB, Robbins R, Bhutkar A, Cardone R, Zhao X, Babic A, Vayrynen SA, Dias Costa A, Nowak JA, Chang DT, Dunne RF, Hezel AF, Koong AC, Wilhelm JJ, Bellin MD, Nylander V, Gloyn AL, McCarthy MI, Kibbey RG, Krishnaswamy S, Wolpin BM, Jacks T, Fuchs CS, Muzumdar MD. Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. Cell 2020, 181: 832-847.e18. PMID: 32304665, PMCID: PMC7266008, DOI: 10.1016/j.cell.2020.03.062.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAnimalsCarcinogenesisCarcinoma, Pancreatic DuctalCell LineCell Line, TumorCell Transformation, NeoplasticDisease Models, AnimalDisease ProgressionEndocrine CellsExocrine GlandsFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMice, Inbred C57BLMutationObesityPancreatic NeoplasmsSignal TransductionTumor MicroenvironmentConceptsPancreatic ductal adenocarcinomaPDAC progressionDuctal adenocarcinomaMajor modifiable risk factorModifiable risk factorsBeta cell expressionObesity-associated changesAutochthonous mouse modelPancreatic ductal tumorigenesisDriver gene mutationsPeptide hormone cholecystokininRisk factorsPDAC developmentMouse modelObesityHormone cholecystokininOncogenic KrasCell expressionTumor microenvironmentDietary inductionCancer developmentGene mutationsReversible roleMurine samplesProgression
2024
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer
Cecchini M, Salem R, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend J, Cai G, Chowdhury S, Yugawa D, Tseng R, Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan S, Cha C, Billingsley K, Kunstman J, Johung K, Wiess C, Muzumdar M, Spickard E, Aushev V, Laliotis G, Jurdi A, Liu M, Escobar-Hoyos L, Lacy J. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer. JAMA Oncology 2024, 10: 1027-1035. PMID: 38900452, PMCID: PMC11190830, DOI: 10.1001/jamaoncol.2024.1575.Peer-Reviewed Original ResearchCitationsAltmetricConceptsProgression-free survivalPancreatic ductal adenocarcinomaOverall survivalCtDNA levelsPhase 2 nonrandomized controlled trialAnalysis of circulating tumor DNAMedian progression-free survivalResectable pancreatic ductal adenocarcinomaControlled trialsAssess surgical candidacyBaseline ctDNA levelModified 5-fluorouracilResectable pancreatic cancerPancreatic protocol computed tomographyAssociated with recurrenceTumor molecular featuresAggressive malignant tumorKaplan-Meier estimatesRandomized clinical trialsStandard of careCtDNA-positivePreoperative cyclesNonrandomized controlled trialsUnresectable diseaseModified FOLFIRINOX994 NANOSTRING GEOMX SPATIAL TRANSCRIPTOMIC ANALYSIS OF PANCREATIC ISLETS IN DIABETIC AND NONDIABETIC PANCREATIC CANCER PATIENTS REVEALS BETA CELL DEDIFFERENTIATION ASSOCIATED WITH ER STRESS PATHWAYS AND ALTERED LIPID METABOLISM
Waldron R, Lugea A, Yong J, Muranaka H, Che M, Ramanujan V, Muzumdar M, Kaufman R, Pandol S. 994 NANOSTRING GEOMX SPATIAL TRANSCRIPTOMIC ANALYSIS OF PANCREATIC ISLETS IN DIABETIC AND NONDIABETIC PANCREATIC CANCER PATIENTS REVEALS BETA CELL DEDIFFERENTIATION ASSOCIATED WITH ER STRESS PATHWAYS AND ALTERED LIPID METABOLISM. Gastroenterology 2024, 166: s-242. DOI: 10.1016/s0016-5085(24)01042-4.Peer-Reviewed Original ResearchImaging nanoscale-spatial oligomeric organization of membrane proteins directly from native membranes at single-molecule resolution
Walker G, Brown C, Ge X, Kumar S, Muzumdar M, Gupta K, Bhattacharyya M. Imaging nanoscale-spatial oligomeric organization of membrane proteins directly from native membranes at single-molecule resolution. Biophysical Journal 2024, 123: 348a. DOI: 10.1016/j.bpj.2023.11.2115.Peer-Reviewed Original Research
2023
Oligomeric organization of membrane proteins from native membranes at nanoscale spatial and single-molecule resolution
Walker G, Brown C, Ge X, Kumar S, Muzumdar M, Gupta K, Bhattacharyya M. Oligomeric organization of membrane proteins from native membranes at nanoscale spatial and single-molecule resolution. Nature Nanotechnology 2023, 19: 85-94. PMID: 38012273, PMCID: PMC10981947, DOI: 10.1038/s41565-023-01547-4.Peer-Reviewed Original ResearchCitationsAltmetricConceptsMembrane proteinsNative membranesOligomeric organizationDiverse membrane proteinsMembrane protein biologyNative cell membranesTarget membrane proteinsNative membrane environmentSingle-molecule resolutionSingle-molecule platformReceptor tyrosine kinasesOligomeric distributionNative nanodiscsOligomerization statusProtein biologySmall GTPaseGrowth factor bindingMembrane environmentOligomeric assembliesTyrosine kinaseCritical regulatorOncogenic mutationsCell membraneProteinMembraneDecoding the obesity–cancer connection: lessons from preclinical models of pancreatic adenocarcinoma
Ruiz C, Garcia C, Jacox J, Lawres L, Muzumdar M. Decoding the obesity–cancer connection: lessons from preclinical models of pancreatic adenocarcinoma. Life Science Alliance 2023, 6: e202302228. PMID: 37648285, PMCID: PMC10474221, DOI: 10.26508/lsa.202302228.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPancreatic adenocarcinomaPreclinical modelsObesity-cancer connectionObesity-associated cancersMicrobial dysbiosisHormone dysregulationEarly progressionRisk factorsWorldwide prevalencePancreatic tumorigenesisObesityPreclinical modelingCancer typesCancer developmentTumor cellsAdenocarcinomaTumor initiationCancerMetabolic stateCellular metabolismNovel strategyDysbiosisInflammationTherapyPrevalenceIntegrated Physiology of the Exocrine and Endocrine Compartments in Pancreatic Diseases: Workshop Proceedings.
Mastracci T, Apte M, Amundadottir L, Alvarsson A, Artandi S, Bellin M, Bernal-Mizrachi E, Caicedo A, Campbell-Thompson M, Cruz-Monserrate Z, El Ouaamari A, Gaulton K, Geisz A, Goodarzi M, Hara M, Hull-Meichle R, Kleger A, Klein A, Kopp J, Kulkarni R, Muzumdar M, Naren A, Oakes S, Olesen S, Phelps E, Powers A, Stabler C, Tirkes T, Whitcomb D, Yadav D, Yong J, Zaghloul N, Pandol S, Sander M. Integrated Physiology of the Exocrine and Endocrine Compartments in Pancreatic Diseases: Workshop Proceedings. Diabetes 2023, 72: 433-448. PMID: 36940317, PMCID: PMC10033248, DOI: 10.2337/db22-0942.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPancreatic diseaseEndocrine compartmentExocrine diseaseBasic science investigatorsExocrine disorderIntegrated physiologyMetabolic influencesExocrine pancreasDiseaseDisease mechanismsNormal physiologyNational InstitutePancreas anatomyGenetic driversPancreasMultiple presentationsExocrineCurrent knowledge
2022
Integrated Physiology of the Exocrine and Endocrine Compartments in Pancreatic Diseases
Mastracci T, Apte M, Amundadottir L, Alvarsson A, Artandi S, Bellin M, Bernal-Mizrachi E, Caicedo A, Campbell-Thompson M, Cruz-Monserrate Z, Ouaamari A, Gaulton K, Geisz A, Goodarzi M, Hara M, Hull-Meichle R, Kleger A, Klein A, Kopp J, Kulkarni R, Muzumdar M, Naren A, Oakes S, Olesen S, Phelps E, Powers A, Stabler C, Tirkes T, Whitcomb D, Yadav D, Yong J, Zaghloul N, Sander M, Pandol S. Integrated Physiology of the Exocrine and Endocrine Compartments in Pancreatic Diseases. Pancreas 2022, 51: 1061-1073. PMID: 37078927, PMCID: PMC10328394, DOI: 10.1097/mpa.0000000000002170.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and Concepts
2021
5‐Fluorouracil efficacy requires anti‐tumor immunity triggered by cancer‐cell‐intrinsic STING
Tian J, Zhang D, Kurbatov V, Wang Q, Wang Y, Fang D, Wu L, Bosenberg M, Muzumdar MD, Khan S, Lu Q, Yan Q, Lu J. 5‐Fluorouracil efficacy requires anti‐tumor immunity triggered by cancer‐cell‐intrinsic STING. The EMBO Journal 2021, 40: e106065. PMID: 33615517, PMCID: PMC8013832, DOI: 10.15252/embj.2020106065.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAnti-tumor immunityTumor burdenSubsequent type I interferon productionHigh STING expressionIntratumoral T cellsT-cell depletionType I interferon productionI interferon productionLoss of STINGImmunocompetent hostsColorectal specimensT cellsSTING expressionBetter survivalHigh doseTherapeutic effectivenessHuman colorectal specimensMelanoma tumorsInterferon productionChemotherapeutic drugsMurine colonImmunityEfficacyStingsColon
2019
Identification of DHODH as a therapeutic target in small cell lung cancer
Li L, Ng SR, Colón CI, Drapkin BJ, Hsu PP, Li Z, Nabel CS, Lewis CA, Romero R, Mercer KL, Bhutkar A, Phat S, Myers DT, Muzumdar MD, Westcott PMK, Beytagh MC, Farago AF, Vander Heiden MG, Dyson NJ, Jacks T. Identification of DHODH as a therapeutic target in small cell lung cancer. Science Translational Medicine 2019, 11 PMID: 31694929, PMCID: PMC7401885, DOI: 10.1126/scitranslmed.aaw7852.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdenocarcinomaAnimalsBiphenyl CompoundsCarcinoma, Pancreatic DuctalCell Line, TumorDCMP DeaminaseDihydroorotate DehydrogenaseDisease ProgressionEnzyme InhibitorsHumansLung NeoplasmsMiceMolecular Targeted TherapyOxidoreductases Acting on CH-CH Group DonorsPancreatic NeoplasmsPyrimidinesSmall Cell Lung CarcinomaSurvival AnalysisXenograft Model Antitumor AssaysConceptsSmall cell lung cancerCell lung cancerPancreatic ductal adenocarcinomaLung cancerLung adenocarcinomaMouse modelSCLC cellsTherapeutic targetHuman patient-derived xenograft modelsAggressive lung cancer subtypePatient-derived xenograft modelsLung cancer subtypesAutochthonous mouse modelPotential therapeutic targetSCLC tumor growthGenetic driver eventsTreatment landscapePoor prognosisDuctal adenocarcinomaXenograft modelCancer subtypesTumor growthPharmacological inhibitionDihydroorotate dehydrogenaseGenetic vulnerability
Academic Achievements and Community Involvement
honor Damon Runyon-Rachleff Innovation Award
National AwardDamon Runyon Cancer Research FoundationDetails01/01/2021United Stateshonor New Innovator Award (DP2)
National AwardNational Institutes of Health Director's Common FundDetails10/01/2019United Stateshonor AACR NextGen Grant for Transformative Cancer Research
National AwardAmerican Association for Cancer ResearchDetails07/01/2019United Stateshonor Early Career Award
National AwardAmerican Association for Cancer Research (journal Cancer Research)Details03/30/2019United Stateshonor Mentored Clinical Scientist Research Career Development Award (K08)
National AwardNational Cancer Institute (NCI)Details07/01/2016United States
Clinical Care
Overview
Mandar Deepak Muzumdar, MD, is a medical oncologist who specializes in gastrointestinal cancer, which is something that affected his life at a young age.
“My father passed away from duodenal (small intestine) cancer. This personal experience along with the exciting advances in cancer biology and cancer care over the last two decades drove me towards a career in oncology,” Dr. Muzumdar says.
In addition to clinical care, he researches pancreatic and lung cancers, and works with fellows, residents, interns, medical students, and graduate students.
“This work diversity allows me to make scientific discoveries and train the next generation of scientists and clinicians in hopes of making a greater impact on the care of patients with cancer,” Dr. Muzumdar says. “Having the opportunity to work with and give back to such diverse and amazing colleagues, trainees, and patients drives my work in research, education, and clinical care.”
Dr. Muzumdar’s laboratory explores the mechanisms by which genetic, environmental, and host factors contribute to cancer initiation, progression, and maintenance. The ultimate goal is to identify novel approaches for cancer prevention and treatment.
Clinical Specialties
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileLinks & Media
Media
News
- June 20, 2024
Chemotherapy Before Surgery Benefits Some Patients With Pancreatic Cancer
- November 17, 2023
Smilow Shares: Pancreatic Cancer Awareness Day
- November 17, 2023
Cancer Metabolism Symposium
- January 17, 2023
Damon Runyon awards $3.2M to innovative early-career scientists
Get In Touch
Contacts
Genetics
Department of Genetics, P.O. Box 208005
New Haven, CT 06520-8005
United States
Administrative Support
Locations
Yale Cancer Biology Institute
Academic Office
West Campus Advanced Biosciences Center
840 West Campus Drive
West Haven, CT 06516
Yale Cancer Biology Institute
Lab
West Campus Advanced Biosciences Center
840 West Campus Drive
West Haven, CT 06516
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.